Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience

Yair Herishanu, Tamar Tadmor, Andrei Braester, Osnat Bairey, Ariel Aviv, Naomi Rahimi-Levene, Riva Fineman, Itai Levi, Mona Yuklea, Rosa Ruchlemer, Lev Shvidel, Aaron Polliack

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases